Check for updates

RESEARCH ARTICLE

REVISED Narcolepsy in Parkinson's disease with insulin resistance [version 2; peer review: 2 approved, 1 approved with reservations]

Alisha Chunduri ^{1,2}, Wim E. Crusio ^{3,4}, Anna Delprato ^{2,3}

¹Department of Biotechnology, Chaitanya Bharathi Institute of Technology, Hyderabad, 500075, India

²Department of Research and Education, BioScience Project, Wakefield, MA, 01880, USA

³Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, CNRS UMR 5287, Pessac, 33615, France

⁴Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR 5287 University of Bordeaux, Pessac, 33615, France

v2 First published: 23 Nov 2020, 9:1361
<https://doi.org/10.12688/f1000research.27413.1>
 Second version: 20 Oct 2021, 9:1361
<https://doi.org/10.12688/f1000research.27413.2>
 Latest published: 20 Jan 2022, 9:1361
<https://doi.org/10.12688/f1000research.27413.3>

Abstract

Background: Parkinson's disease (PD) is characterized by its progression of motor-related symptoms such as tremors, rigidity, slowness of movement, and difficulty with walking and balance. Comorbid conditions in PD individuals include insulin resistance (IR) and narcolepsy-like sleep patterns. The intersecting sleep symptoms of both conditions include excessive daytime sleepiness, hallucinations, insomnia, and falling into REM sleep more quickly than an average person. Understanding of the biological basis and relationship of these comorbid disorders with PD may help with early detection and intervention strategies to improve quality of life.

Methods: In this study, an integrative genomics and systems biology approach was used to analyze gene expression patterns associated with PD, IR, and narcolepsy in order to identify genes and pathways that may shed light on how these disorders are interrelated. A correlation analysis with known genes associated with these disorders (*LRRK2*, *HLA-DQB1*, and *HCRT*) was used to query microarray data corresponding to brain regions known to be involved in PD and narcolepsy. This includes the hypothalamus, dorsal thalamus, pons, and subcoeruleus nucleus. Risk factor genes for PD, IR, and narcolepsy were also incorporated into the analysis.

Results: The PD and narcolepsy signaling networks are connected through insulin and immune system pathways. Important genes and pathways that link PD, narcolepsy, and IR are *CACNA1C*, *CAMK1D*, *BHLHE41*, *HMGB1*, and AGE-RAGE.

Conclusions: We have identified the genetic signatures that link PD with its comorbid disorders, narcolepsy and insulin resistance, from the convergence and intersection of dopaminergic, insulin, and

Open Peer Review

Approval Status

	1	2	3
version 3			
(revision)			
20 Jan 2022	view		view
version 2			
(revision)			
20 Oct 2021		view	view
version 1			
23 Nov 2020			
	view	view	view

1. **Makoto Hashimoto** , Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
2. **Qing Wang** , Zhujiang Hospital, Southern Medical University, Guangzhou, China
3. **Daniel Enterría-Morales** , University of California San Diego, La Jolla, USA

Any reports and responses or comments on the article can be found at the end of the article.

immune system related signaling pathways. These findings may aid in the design of early intervention strategies and treatment regimes for non-motor symptoms in PD patients as well as individuals with diabetes and narcolepsy.

Keywords

Parkinson's disease, narcolepsy, insulin resistance, diabetes, circadian

This article is included in the **Circadian Clocks in Health and Disease** collection.

Corresponding author: Anna Delprato (adelprato@bioscienceproject.org)

Author roles: **Chunduri A:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Resources, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Crusio WE:** Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Delprato A:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Chunduri A *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Chunduri A, Crusio WE and Delprato A. **Narcolepsy in Parkinson's disease with insulin resistance [version 2; peer review: 2 approved, 1 approved with reservations]** F1000Research 2021, 9:1361 <https://doi.org/10.12688/f1000research.27413.2>

First published: 23 Nov 2020, 9:1361 <https://doi.org/10.12688/f1000research.27413.1>

REVISED Amendments from Version 1

We are submitting a revised version of our manuscript entitled: Narcolepsy in Parkinson's disease with insulin resistance. In this version we have addressed each of the reviewer's concerns and recommendations.

Specifically, we have revised the Introduction and Discussion sections to include additional context and mechanistic details. We have also expanded the bibliography based on many references provided by the reviewers.

There are new gene expression data provided to further strengthen our findings. The gene expression data are summarized in a table which is included in the main body of the revised manuscript. The raw data are provided as Extended data files. The Methods, Results and Discussion sections have been updated to incorporate this information. The figures and other files which were included in the original version have not been edited.

Any further responses from the reviewers can be found at the end of the article

Introduction

Parkinson's disease (PD) is characterized by its progression of motor-related symptoms such as tremors, rigidity, slowness of movement, and difficulty with walking and balance¹⁻³. The motor difficulties associated with PD are attributed to the loss of dopaminergic neurons in the substantia nigra^{1,4}. There are also non-dopamine lesions that are involved in PD that include the caudal group of intralaminar nuclei (located in dorsal thalamus), and subcoeruleus nuclei^{1,2}. The main genetic cause of PD is attributed to mutation of the *LRRK2* (leucine-rich repeat kinase 2) gene^{5,6}.

There is also a significantly increased risk of PD among patients with a history of diabetes and PD associated motor symptoms and cognitive decline are accelerated in individuals with diabetes^{7,8}). Results from numerous studies investigating the connection between diabetes and PD indicate that there is an overlap in disease mechanisms and pathways particularly in the context of the accumulation of misfolded proteins^{2,9}, defects in mitochondrial function leading to oxidative stress^{10,11}, immune system activation resulting in inflammation¹²⁻¹⁴, reduced synaptic plasticity, and a decrease in dopamine levels^{15,16}. Dopamine signaling is also linked to circadian rhythm and sleep¹⁷. Studies demonstrate that dopamine levels cycle in a circadian manner in the retina, olfactory bulb, striatum, midbrain, and hypothalamus¹⁷⁻²⁰. Disrupted sleep patterns and circadian rhythm are also associated with many neuropsychiatric and neurodegenerative illnesses including *LRRK2*-PD and it is often more disturbing than the motor symptoms²¹⁻²³.

Most PD patients have daytime sleep attacks and REM sleep disorder that resemble narcolepsy associated sleep symptoms such as excessive daytime drowsiness, sleep paralysis, hallucinations²⁴, and in some cases episodes of cataplexy²⁵. People with narcolepsy frequently enter REM sleep rapidly, within 15 minutes of falling asleep and the muscle weakness or dream activity of REM sleep can occur during wakefulness

or be absent during sleep²⁶. Alleles of the *HLA-DQB1* (major histocompatibility complex, class II, DQ beta 1) gene are associated with a predisposition to narcolepsy²⁷, PD²⁸, and Type I diabetes²⁹.

Besides *HLA-DQB1*, the relationship between PD, narcolepsy, and IR may be in part attributed to the hypocretins/orexins which are produced by the *HCRT* gene³⁰. Hypocretins are neurotransmitters that are manufactured by a small number of neurons in the hypothalamus³¹. They act to stimulate target neurons and promote wakefulness while suppressing rapid-eye-movement (REM) sleep³². Research has shown that there is a massive loss of hypocretin neurons in patients of both PD and narcolepsy and it is hypothesized that the reduction of hypocretin may be the underlying pathogenesis of the narcoleptic symptoms in PD^{24,32,33}. In addition to their role in narcolepsy and PD, hypocretins modulate glucose and insulin metabolism³³ and also play a critical role in dopamine regulation³⁴. In this study we explore the connection between PD, narcolepsy, and IR using an integrative genomics and systems biology approach.

Methods

Genesets and evaluation

Microarray data was collected from the [Allen Brain Database](#) using the Human Brain Atlas. To obtain the data, a gene search for *LRRK2*, *HLA-DQB1*, and *HCRT* was performed. Each of these genes were used to query the atlas for correlates to the hypothalamus, dorsal thalamus, pons, and subcoeruleus nucleus using the dropdown menu for each of the six donor post-mortem brains available in the Allen Human Brain Atlas.

Genes whose expression pattern correlated with *LRRK2*, *HLA-DQB1*, and *HCRT* were collected for analysis. Correlates with a range of Pearson *r* values from 0.6 to 1.0 were considered in the analysis (*Extended data*, Workbook 1³⁵). The rationale was to investigate genes with a similar expression pattern in order to identify gene correlates specific and common to *LRRK2*, *HLA-DQB1*, and *HCRT*. Risk factor genes and genes contributing to PD, narcolepsy, and IR were obtained from OMIM, [Harmonizome](#), and [GeneWeaver](#).

Each geneset was evaluated using Gene Ontology (GO) enrichment for clustering, pathways, and keywords using the [Database for Annotation, Visualization and Integrated Discovery](#) (DAVID, version 6.8) and the [Gene Ontology](#) databases with integrated tools for analysis. Clustering was done in DAVID using the default parameters which include medium stringency settings and a kappa similarity value of 3. The Benjamini corrected P-value was used to determine enrichment significance. The pathway enrichment was performed using KEGG and Panther pathways. The pathways were analyzed manually and evaluated based on shared themes. For the keyword enrichment, a keyword search of the DAVID functional annotation table output was used to identify genes associated with relevant traits related to *LRRK2*, *HLA-DQB1*, and *HCRT* function. The keywords considered were 'sleep', 'circadian', 'parkinson', 'locomotion', 'dopamine', 'behavior', 'learning', 'memory', and 'transcription factor'. Geneset overlap was assessed using

Venny 2.0, an online program that compares lists of items to determine the common and unique genes between *LRRK2*, *HLA-DQB1*, and *HCRT* within and among each brain region (hypothalamus, dorsal thalamus, pons, and subcoeruleus nucleus).

Network analysis

The String database (version 11.0) was used to build a protein-protein interaction network (ppi for *LRRK2*, *HLA-DQB1*, *HCRT* and *CAMK1D* which was identified in this study as the only common risk factor gene associated with PD, narcolepsy and IR (Results section: “Functional analysis of PD, narcolepsy and IR risk factor and related genes”). The network was constructed based on experimentally validated interactions using the medium confidence score of 0.4. The combined scores for the interactions are computed by combining the probabilities from the different evidence channels and corrected for the probability of randomly observing an interaction. First and 2nd shell interactions are included in the network. The network was exported from STRING and analyzed in Cytoscape (version 3.7). Network bottlenecks and clusters were identified with Cytoscape plugins CytoHubba (version 0.1) and MCODE (version 1.6.1), respectively. ClueGo (version 2.5.7) was used to analyze the common risk factors and contributing genes for PD, narcolepsy, and IR. The nodes in the network have been manually arranged for proper visibility. Select enriched terms are included in the network (Figure 3A). All of the enriched terms are provided in *Extended data*, Workbook 5, sheet 5³⁶. Legacy data sets from the Human Protein Atlas (HPA) (<https://www.proteinatlas.org/>) along with gene expression data from the Allen Brain Atlas were used to assess the expression patterns of key genes identified in the ppi network. To assess gene expression of the key network genes in the relevant brain regions considered in this study, we examined microarray data from the Human Allen Brain Atlas for the dorsal thalamus and subcoeruleus nucleus and the HPA for the hypothalamus and pons. Two data sources were used because the Allen Brain Atlas RNA-Seq data did not provide enough samples to evaluate the gene expression in the hypothalamus and pons for these genes. The RNA-Seq data for the dorsal thalamus and subcoeruleus nucleus are derived from either 5 or 6 postmortem donor brains of varying ages and gender. In most instances the genes are sampled multiple times using different probes. The data are expressed as Z score log2 transformed and indicate the number of standard deviations away from the mean. The data across probes was not combined for statistical analysis because it is qualitative but we calculated the percentage of reads with a positive value which measures the detection of RNA at or above the standards used in the assay. This is not to say that the negative values (Number of standard deviations away from the mean) indicate that RNA is not detected.

The HPA includes RNA-Seq data from humans, mouse and pig. Human data are derived from the Genotype-Tissue Expression (GTEx) (<https://www.gtexportal.org/home/>) and Functional Annotation of Mammalian Genomes 5 (FANTOM5) projects. Mouse and Pig RNA-Seq data were generated by the Beijing Genomics Institute (<https://www.bgi.com/global/>) in collaboration with the HPA). Assay conditions are provided in detail

at the HPA (<https://www.proteinatlas.org/about/assays+annotation#transcriptomics>).

Results

Functional analysis of gene correlates

The cluster analysis for the *LRRK2*, *HLA-DQB1*, and *HCRT* gene correlates for each brain region resulted in significant enrichment categories for only the *HLA-DQB1* related gene-sets. For *LRRK2* and *HCRT* there are several instances in which clusters contained enrichment terms for insulin, diabetes, PD, other neurodegenerative disorders, and circadian processes but these did not achieve significance based on the corrected P value criteria. Also, of note for almost every set of correlates, there were many significant enrichment categories and corresponding genes associated with keratinocytes/keratin and olfaction. The clustering results for each set of gene correlates are listed in *Extended data*, Workbook 2³⁷.

For the *HLA-DQB1* clusters, the significant enrichment terms are: dorsal thalamus: hsa05012:Parkinson's disease (P=4.38E-06), 31 genes and hsa04940:Type I diabetes mellitus (P=0.03), 10 genes; subcoeruleus nucleus: hsa04940:Type I diabetes mellitus (P=6.13E-05), 15 genes, and pons: hsa04940:Type I diabetes mellitus, six genes (P=0.001). The other genes and enrichment categories clustering with PD in the dorsal thalamus are related to mitochondria processes such as oxidative phosphorylation and electron transport as well as Alzheimer's disease (AD) and Huntington disease (HD).

Geneset overlap

Among the sets of gene correlates for *LRRK2*, *HLA-DQB1* and *HCRT*, there are 10 common genes in both the dorsal thalamus and subcoeruleus nucleus (*A_32_P232747*, *DISC1*, *GABRA4*, *GDF11*, *HNRNPU*, *PAK2*, , *PFKFB2*, *ROCK1*, , *SLC9A3R2*, and *ZNF846*, ; Figure 1B). Among the relevant genes are *ROCK1*, which is involved in negative regulation of neuron apoptotic processes, *DISC1* associated with neuron migration, and *HNRNPU* involved in circadian regulation of gene expression. The ten common genes in the subcoeruleus nucleus are *GLYAT*, *HCN4*, *HMGB1*, *HNRNPU*, *ITGB2*, *LAMP2*, *LOC653110*, *OPA3*, *PHTF2*, and *SLC6A6*, , among which the relevant ones to this study are *HNRNPU*, which as mentioned above is involved in circadian regulation of gene expression and insulin signaling, *ITGB2*, which is associated with PD and IR, and *HMGB1*, which is a ligand for the RAGE receptor. Among the sets of gene correlates for *LRRK2*, *HLA-DQB1*, and *HCRT*, there are no common correlated genes in the hypothalamus and pons.

A detailed description of all shared genes and their associated function for each brain region is provided in *Extended data*, Workbook 3 (sheets 1-8)³⁸. Briefly, the dorsal thalamus and subcoeruleus nucleus have the largest number of shared correlates between *LRRK2*, *HCRT*, and *HLA-DQB1*. Many of these genes for both brain regions are associated with neuron, insulin, and dopamine related processes. There are also several genes connected directly to PD. In sharp contrast, however, the dorsal thalamus associated correlates have many genes linked to circadian function.

Figure 1. Geneset Overlap. Shared correlates for LRRK2, HLA-DQB1 and HCRT over all brain regions. X-axis, Intersection size; Y-axis, Genes and brain regions.

In the dorsal thalamus, the relevant genes are associated with neuron function (negative regulation of neuron apoptotic process, neuron projection development and regulation, neuron differentiation, neuron fate commitment, neuron death in response to oxidative stress, neuron regeneration), circadian processes (regulation of circadian rhythm, circadian entrainment, circadian regulation of gene expression, regulation of circadian rhythm, entrainment of circadian clock by photoperiod), and insulin signaling (insulin secretion, insulin receptor signaling, insulin secretion). Other genes of interest are related to dopamine (dopaminergic neuron differentiation, regulation of dopamine uptake involved in synaptic transmission, positive regulation of dopamine secretion, Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation, dopamine receptor binding, dopamine biosynthetic process, adenylate cyclase-activating dopamine receptor signaling pathway) and also behavior (locomotory, feeding, learning, memory and vocalization, response to stimulants).

In the subcoeruleus nucleus, the relevant genes are also associated with neuron function (negative regulation of neuron differentiation, dopaminergic neuron differentiation, neuron apoptotic process, negative regulation of neuron differentiation, fore-brain neuron differentiation), insulin signaling (insulin secretion, insulin receptor signaling pathway, negative regulation of

insulin receptor signaling pathway, positive regulation of insulin secretion, diabetes mellitus), dopamine related processes (dopaminergic synapse, dopamine biosynthetic process, dopaminergic neuron differentiation, regulation of synaptic transmission, dopaminergic dopamine biosynthetic process from tyrosine), and behavior (locomotory, vocal learning, response to fear, grooming, response to stimulants).

There are few shared correlated genes in the hypothalamus and pons. For the hypothalamus, the most pertinent genes are involved in neuron migration and circadian processes. In the pons, the relevant genes are concerned with negative regulation of neuron apoptotic processes, neuron projection, circadian regulation of gene expression, and hippocampus and pyramidal neuron development.

Geneset overlap of the correlates for *LRRK2*, *HLA-DQB1*, and *HCRT* was assessed within each brain region (see *Extended data*, Workbook 3, sheets 9-11)³⁸. Of the *LRRK2* correlates, 1.6% were common in all 4 brain regions. Among these are genes associated with insulin (*MAX*, *NUCKS1*, *PIK3R1*, *PTPN11*), diabetes (*PIK3R1*) and circadian-related processes (*HNRNPU*, *BHLHE41*). Several transcription factors were also present (*MAX*, *SKI*, *ATF7IP*, *NUCKS1*, *BHLHE41*, *NR2C2*, *PIK3R1*). One of these, *BHLHE41*, acts as a negative regulator of orexin,

controls circadian rhythms, and is associated with short sleep syndrome and advanced sleep phase disorder. For *HLA-DQB1*, 1.2% of the correlates are common in all brain regions; relevant associated themes include PD and dopamine (*SLC18A1*) insulin (*HLA-DRB5*, *HLA-DOA*, *HLA-DQA1*, *HLA-DQB1*) and transcription factors (*FOXE3*, *HMGB1*, *LGALS9*, *PYCARD*, *SOX8*, *ZNF446*). Only 0.2% of the *HCRT* correlates are common among all brain regions considered. This includes *HCRT* itself and an insulin associated gene, *GHSR*. Of note, the *MOG* gene, which is present among the *HLA-DQB1* correlates of the subcoeruleus nucleus and *HCRT* correlates of the hypothalamus, is a risk factor for narcolepsy and is linked to PD.

Keyword evaluation of gene correlates

From the GO analysis of the gene correlates, a functional annotation table was generated for GO Biological Process. Genes associated with keywords were obtained and their frequencies determined. The keyword categories used are as follows: sleep, circadian, Parkinson, locomotion, dopamine, insulin, behavior, learning, memory, and transcription factor (Figure 2A–C and Extended data, Workbook 4, sheets 1–6)³⁹. Each of the correlates for the genesets are evaluated for keywords related to the phenotypes of narcolepsy, PD, and IR in the hypothalamus, dorsal thalamus, pons, and subcoeruleus nucleus. Most of the keywords of the three sets of gene correlates are associated with subcoeruleus nucleus.

The *LRRK2* gene correlates have the highest frequency of the keyword categories. The highest represented categories are: transcription factor (hypothalamus), insulin, behavior, learning, memory, locomotion (dorsal thalamus), dopamine, Parkinson, and sleep (subcoeruleus nucleus) and circadian processes (equal frequency in dorsal thalamus and subcoeruleus nucleus).

The highest represented keyword categories for *HLA-DQB1* are behavior, insulin, transcription factor, circadian, memory, dopamine, sleep (subcoeruleus nucleus), locomotion (hypothalamus), and learning (equal frequencies in the hypothalamus and subcoeruleus nucleus). The highest represented categories of *HCRT* are transcription factor, behavior, insulin, circadian, dopamine, Parkinson, memory, sleep, locomotion (subcoeruleus nucleus), and learning (hypothalamus).

Functional analysis of PD, narcolepsy, and IR risk factor and related genes

PD, narcolepsy, and IR risk factor and related genesets were evaluated to identify a common set of genes associated with the three disorders (Extended data, Workbook 5, sheets 1–4)³⁶. There were 38 shared genes between the PD and narcolepsy genesets. *CAMK1D* is the only gene common among the 3 genesets for PD, narcolepsy, and IR and it is a Calcium/Calmodulin kinase that is upregulated in PD patients and is also a risk factor for Type 2 diabetes^{40,41}.

Of the common PD and narcolepsy genes, several were directly associated with PD and narcolepsy behavioral phenotypes such as locomotion (*DRD2*, *DRD3*, *DRD4*, *GDNF*, *SLC18A2*), sleep (*DRD2*, *DRD3*, *GRIN2A*, *HTR2A*, *NLGN1*), circadian processes

(*CACNA1C*, *DRD2*, *DRD3*, *DRD4*, *GRIN2*, *MAPK1*, *NLGN1*, *PPARGC1A*), circadian entrainment (*CACNA1C*, *GRIN2A*, *MAPK1*), learning (*COMT*, *DRD1*, *DRD2*, *DRD3*, *GRIN2A*) and memory (*COMT*, *DRD1*, *DRD2*, *DRD3*, *GRIN2A*, *HTR2A*). There were two common genes between the PD and IR genesets: *RREB1*, which is a transcription factor, and *ANKFY1*, which is involved in vesicle trafficking and is also implicated in Type 2 diabetes. There is one common gene between narcolepsy and IR: *HLA-DQB1*, which is the narcolepsy associated gene under study here.

The enrichment results are visualized as a network of functionally grouped terms and pathways and listed in the accompanying bar graph (Figure 3A, B, Extended data, Workbook 5, sheet 5)³⁶. The most significant term of a given group is highlighted as the leading term in the network which is indicated by color. The most significant terms emphasized in the graph are dopaminergic synapse (ten genes, KEGG ID:04728, P=2.77E-09) and the AGE-RAGE signaling pathway in diabetic complications (seven genes, KEGG ID:04933, P=4.70E-06) both of which are relevant to PD and IR. Other relevant enriched GO Terms include Type I diabetes mellitus (four genes, KEGG:04940, P=6.27E-04), Type II diabetes mellitus (four genes, KEGG:04930, P=7.54E-04), and Amyotrophic lateral sclerosis (five genes, KEGG:05014, P=9.56E-05). The other enriched terms in the network also represent pathways linked to the reward system, serotonin signaling, immune system function, and insulin regulation. There are several points of convergence in the graph where the enriched terms overlap: AGE-RAGE, Sphingolipid, and Fc Epsilon RI signaling pathways as well as long term potentiation. (Extended data, Workbook 5, sheet 5)³⁶.

The PD, narcolepsy, and IR connection

A protein-protein interaction network revealed the insulin connection between the *LRRK2* and *HLA-DQB1* networks using the multiple protein option in the STRING database (Figure 4A, Extended data, Workbook 6, sheets 1–2)⁴². The distribution for the PPI scores for each show that the majority of the interactions fall in the high range with scores between 0.7 and 1.0 (Figure 4B). Insulin (INS) and its receptor (INSR) are connected to *HLA-DQB1* through 1st shell interactions both of which are based on crystallographic evidence. *INSR* is in turn connected to *CALM1*, a calmodulin binding protein involved in calcium signaling and associated with diverse processes including circadian entrainment (KEGG pathway 04713). The evidence for the *INSR/CALM1* interaction is based on coimmunoprecipitation, electro mobility shift, and western blot assays. Relevant interactions, scores, and references are provided in Table 1.

In the network, *CALM1* bridges *INSR*, *CAMK1D* (the only common gene among the database curated genesets for PD, narcolepsy, and IR), and *LRRK2*. The *CALM1* and *CAMK1D* relationship is supported by coimmunoprecipitation and filter binding and phage display assays. The *CALM1/LRRK2* interaction is supported by cosedimentation, coimmunoprecipitation and genetic interference assays.

There are many proteins in the network related to insulin signaling (*CACNA1C*, *CALM1*, *CALM2*, *CALM3*, *IDE*, *IGF1*, *IGF1R*,

Figure 2. Keyword Enrichment. Representative keyword enrichment of the gene correlates of LRRK2, HLA-DQB1 and HCRT in the Hypothalamus, Dorsal Thalamus, Pons and Nucleus Subcoeruleus based on GO term classification. (A) LRRK2 gene correlates (B) HLA-DQB1 gene correlates (C) HCRT gene correlates. X-axis, keyword categories; Y-axis, frequency of occurrence.

Figure 3. Enrichment Network Analysis. (A) Risk factors enrichment network. In the network the color gradient indicates the proportion of genes in each cluster associated with the enriched GO term. Dark blue nodes include dopaminergic synapse and pathways related to the reward system. Cyan nodes include the AGE-RAGE Signaling pathway in diabetic complications, immune system pathways and lipid signaling. Magenta nodes involve terms associated with immune system function and also insulin signaling. (B) GO pathway terms and associated genes. Bar graph showing the percentage of genes connected with the GO terms. Bars are colored according to the network (Figure 3A).

INSRR, *INS-IGF2*, *KCNN2*, *PRKCE*, *RAF1*, *YWHAH*, *YWHAH*). Several genes are implicated in AD (*CACNA1C*, *CALM1*, *CALM2*, *CALM3*, *IDE*), circadian entrainment (*CACNA1C*, *CALM1*, *CALM2*, *CALM3*), and dopamine signaling (*CACNA1C*, *CALM1*, *CALM2*, *CALM3*, *LRRK2*). *LRRK2* is the only gene in the network linked to PD. There were no experimentally validated interacting partners for *HCRT* and it did not connect to the network.

Results for gene expression of the key genes in the hypothalamus, and pons, are as follows: Each of the genes with the exception of *AGER* were expressed in both the hypothalamus and pons for human, mouse and pig. *CACNA1C* expression was also confirmed at the protein level by immunocytochemistry in the mouse hypothalamus and pons/medulla. Data are provided in *Extended data*, Table 1. The expression pattern of the key genes in dorsal thalamus and subcoeruleus nucleus data were obtained for humans only and are as follows: *HMGB1*, *AGER*, *BHLHE41* are expressed in both the dorsal thalamus and subcoeruleus nucleus. *CACNA1C* is expressed in the dorsal thalamus but is not expressed in the subcoeruleus nucleus. *CAMK1D* was not expressed in either the dorsal thalamus or subcoeruleus nucleus. The results from the gene expression data are summarized in Table 2, Data for the dorsal thalamus and subcoeruleus nucleus are provided in *Extended data*, workbook 7⁴³.

Discussion

The aim of this study is to identify the underlying genes and pathways linking PD, narcolepsy, and IR. An integrative genomics and systems biology approach was used for the analysis of gene expression patterns of the *LRRK2*, *HLA-DQB1*, and *HCRT* genes which are strongly associated with each of these disorders. A comparison of the shared gene correlates for sleep, neurodegeneration, behavior, and insulin led to the identification of genes such as *AGER*, *BHLHE41*, *CACNA1C*, *CAMK1D*, and *HMGB1*, whose defects might be plausible for the narcoleptic-like symptoms in PD and the relationship with IR.

The ppi network of *LRRK2*, *HLA-DQB1*, and *CAMK1D* reveals a connection with several insulin/diabetes, circadian, and PD risk factor genes supporting our hypothesis that these three disorders have common pathogenetic processes and further supports earlier studies that have reported a relationship between these conditions. There is a great deal of evidence derived from knockout and cell based studies linking *AGER*, *CACNA1C* and *HMGB1* to Parkinson's pathogenesis. *CACNA1C* is also associated with circadian rhythm and narcolepsy.

There is also evidence of disrupted calcium homeostasis in PD⁴⁴. Genetic variants of *CACNA1C* which is a subunit of Cav1.2 Ca²⁺ channels. are linked to greater PD risk which

Figure 4. PPI network linking narcolepsy and Parkinson's through insulin. (A) PPI network showing the insulin interaction with the Narcolepsy gene (HLA-DQB1) and Parkinson's disease gene (LRRK2.) (B) Interaction score distribution, X-axis, interaction score; Y-axis, frequency.

is dependent on vitamin D deficiency⁴⁵. Microglia in an induced PD model exhibited enhanced neuroinflammation and inhibited neuroprotection in the presence of a Ca2+ agonist⁴⁶.

Degeneration of dopaminergic neurons have also been observed in microglia-specific Cav1.2 knockdown mice intoxicated with MPTP, a neurotoxin that induces PD-like symptoms⁴⁶. CACNA1C was also expressed 3x higher in microglia treated with agents to stimulate neuro inflammation⁴⁶. *CAMK1D*, also associated with Ca2+ signaling, exhibited decreased expression levels in iPSC-derived neurons carrying the *LRRK2* G2019S mutation, the most prevalent genetic cause of late onset PD⁴⁷.

HMGB1 and *AGER* appear to act in concert mediating inflammatory processes that ultimately lead to neuron cell death via NF- κ B signaling⁴⁸. Studies indicate that *HMGB1* is associated with autophagy dysfunction and the degeneration of dopaminergic neurons through interaction with α -synuclein thereby intensifying protein aggregation and in conjunction with RAGE, inflammation and cell death^{49,50}. RAGE initiates signal transduction cascades and activates NF- κ B, increases cytokine expression and also leads to the production of reactive oxygen species^{51,52}. In neuronal cells expressing the G2019S *LRRK2* mutant, RAGE enhanced cell death. Expression of RAGE proteins were also upregulated in the *LRRK2* mutant cells⁵³. *RAGE* is highly expressed in PD patients when compared with age-matched controls⁵¹ and *RAGE* gene variants have been linked to sporadic PD in an Asian population⁵⁴.

Silencing of the RAGE pathway in a mouse model of PD improved neuroinflammation which causes dopaminergic neurodegeneration in PD patients⁵². This is important because the deterioration of dopaminergic neurons in the brain is believed to play a critical role in the development of PD⁶⁰. By the time clinical signs of PD are identified and a diagnosis is made, a large number of dopaminergic neurons have already been lost¹. Dopaminergic neurons are also involved in promoting feeding behavior in the hypoglycemic state which is mediated by insulin receptors in the substantia nigra, indicating that dopaminergic neuronal loss may alter glycemic control^{61,62}. Loss of orexin/hypocretin is also linked to binge-eating behavior, low BMR, and obesity, which is a symptom of narcolepsy⁶³⁻⁶⁵.

BHLHE41, the other gene of interest identified from the ppi network analysis, is a transcription factor associated with circadian processes. Variants of *BHLHE41* have been implicated in short sleep syndrome⁶⁶. *BHLHE41* also has a role in immune function and in addition to *CAMK1D*, *AGER* is implicated in diabetes along with the narcolepsy-related gene, *HLA-DQB1*.

Silencing of the RAGE pathway in a mouse model of PD improved neuroinflammation which causes dopaminergic neurodegeneration in PD patients⁵². This is important because the deterioration of dopaminergic neurons in the brain is believed to play a critical role in the development of PD⁶⁰. By the time clinical signs of PD are identified and a diagnosis is made, a large number of dopaminergic neurons are already lost¹.

Dopaminergic neurons are also involved in promoting feeding behavior in the hypoglycemic state which is mediated by insulin receptors in the substantia nigra, indicating that dopaminergic neuronal loss may alter glycemic control^{61,62}. Loss of orexin/hypocretin is also linked to binge-eating behavior, low BMR, and obesity, which is also a symptom of narcolepsy⁶³⁻⁶⁵.

Further insight into the relationship between PD, IR and disrupted sleep patterns is evident from studies in which the repurposing of treatment for one of these diseases has been used to alleviate symptoms in another. Results from a recent clinical

Table 1. LRRK2, HLA-DQB1 and CAMK1D relevant network interactions and scores.

PPI	Score	References
INS-INSR	0.974	55
CALM1-CAMK1D	0.732	56
INS-HLA-DQB1	0.72	57
CALM1-INSR	0.433	58
CALM1-LRRK2	0.403	59

Table 2. Expression summary of key genes in the hypothalamus, dorsal thalamus, nucleus subcoeruleus and pons.

gene	hypothalamus	dorsal thalamus	nucleus subcoeruleus	pons
AGER	-	+	+	-
BHLHE41	+	+	+	+
CACNA1C	+	+	-	+
CAMK1D	+	-	-	+
HMGB1	+	+	+	+

trial in which PD patients were treated with intranasal insulin, reported that test subjects had improved verbal fluency and motor skills and sleep related symptoms⁶⁷. Insulin is also promising for treating AD symptoms along with growth factors and incretins (orexin) which are a current therapy for T2D⁶⁸. Metformin another anti diabetic drug has been used to treat AD and may have promise for PD as well⁶⁹. Current trends in Biomarkers for disease detection include neuroimaging techniques such as petscan monitoring to glucose uptake in PD patients and also monitoring of oxidative stress and cholesterol metabolism^{70,71}. Melatonin, the naturally occurring hormone that controls sleep and wake cycles, was also found to be beneficial in PD⁷².

There are more than 10 million people worldwide that live with Parkinson's disease. Additional studies aimed at identifying genes and regulatory factors underlying and bridging these comorbid disorders may aid in the design of early intervention and diagnosis strategies, as well as treatment regimes for patients with PD, diabetes, and/or narcolepsy.

Conclusion

We have identified genetic signatures that link PD with its comorbid disorders, narcolepsy and insulin resistance, from the convergence and intersection of dopaminergic, insulin, and immune system related signaling pathways. The resulting genes and pathways identified here are consistent with many published findings and may aid in the design of early intervention strategies and treatment regimes for non-motor symptoms in PD patients as well as individuals with diabetes and narcolepsy.

Data availability

Source data

All data underlying the results are available as part of the article and no additional source data are required.

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Extended data

Figshare: Extended data workbook 1 LRRK2, HLA-DQB1, and HCRT gene correlates.xlsx. (<https://doi.org/10.6084/m9.figshare.13072037.v1>).

This file contains gene correlates of LRRK2, HLA-DQB1 and HCRT in the hypothalamus, dorsal thalamus, pons and nucleus subcoeruleus.

Figshare: Extended data workbook 2 Cluster analysis of gene correlates.xlsx. <https://doi.org/10.6084/m9.figshare.13072103.v1>.

This file contains cluster analysis of gene correlates of LRRK2, HLA-DQB1 and HCRT in the hypothalamus, dorsal thalamus, pons and nucleus subcoeruleus.

Figshare: Extended data workbook 3 Common genes and functions.xlsx. <https://doi.org/10.6084/m9.figshare.13072124.v1>.

This file contains gene set overlap and functional analysis for LRRK2, HLA-DQB1, and HCRT gene correlates.

Figshare: Extended data workbook 4 Keyword genes.xlsx. <https://doi.org/10.6084/m9.figshare.13072130.v1>.

This file contains keyword enrichment of gene correlates of LRRK2, HLA-DQB1 and HCRT.

Figshare: Extended data workbook 5 PD, narcolepsy and IR risk factors genes.xlsx. <https://doi.org/10.6084/m9.figshare.13072151.v1>.

This file contains Parkinson's disease, narcolepsy and Insulin resistance risk factors genes

Figshare: Extended data workbook 6 LRRK2, HLA-DQB1 and CAMK1D protein-protein interaction network.xlsx. <https://doi.org/10.6084/m9.figshare.13072160.v1>.

This file contains LRRK2, HLA-DQB1 and CAMK1D protein-protein interaction network coordinates.

Figshare: Extended data workbook 7 Gene expression patterns for AGER, BHLHE41 CACNA1C, CAMK1D, HMGB1 in the dorsal thalamus and subcoeruleus nucleus.xlsx. <https://doi.org/10.6084/m9.figshare.16680571>.

This file contains dorsal thalamus and subcoeruleus nucleus RNA-Seq data for key genes

Figshare: Extended data Table 1. Hypothalamus_and_Pons gene_expression_for_key_genes. <https://doi.org/10.6084/m9.figshare.16692085>

This file contains hypothalamus and Pons RNA-Seq data for key genes.

Extended data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Author contributions

AC and AD designed the project, AC, AD, and WEC did the formal analysis, writing and editing of the manuscript. All authors approved the final version of the manuscript.

References

1. Lew M: **Overview of Parkinson's disease.** *Pharmacotherapy.* 2007; **27**(12 Pt 2): 1555–1605.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Sveinbjornsdottir S: **The clinical symptoms of Parkinson's disease.** *J Neurochem.* 2016; **139** Suppl 1: 318–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Xia R, Mao ZH: **Progression of motor symptoms in Parkinson's disease.** *Neurosci Bull.* 2012; **28**(1): 39–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Kuechler A, Willemsen MH, Albrecht B, et al.: **De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: expanding the mutational and clinical spectrum.** *Hum Genet.* 2015; **134**(1): 97–109.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. **Non-dopamine Lesions in Parkinson's Disease.** Oxford Medicine. [cited 2021 Sep 25].
[Reference Source](#)
6. Li JQ, Tan L, Yu JT: **The role of the LRRK2 gene in Parkinsonism.** *Mol Neurodegener.* 2014; **9**: 47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Hu G, Jousilahti P, Bidel S, et al.: **Type 2 diabetes and the risk of Parkinson's disease.** *Diabetes Care.* 2007; **30**(4): 842–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Chohan H, Senkevich K, Patel RK, et al.: **Type 2 diabetes as a determinant of parkinson's disease risk and progression.** *Mov Disord.* 2021; **36**(6): 1420–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Mukherjee A, Morales-Scheihing D, Butler PC, et al.: **Type 2 diabetes as a protein misfolding disease.** *Trends Mol Med.* 2015; **21**(7): 439–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Park JS, Davis RL, Sue CM: **Mitochondrial dysfunction in parkinson's disease: new mechanistic insights and therapeutic perspectives.** *Curr Neurol Neurosci Rep.* 2018; **18**(5): 21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Hong CT, Chen KY, Wang W, et al.: **Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α -Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.** *Cells.* 2020; **9**(3): 740.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Wang T, Yuan F, Chen Z, et al.: **Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinson's disease patients with type 2 diabetes mellitus.** *Aging (Albany NY).* 2020; **12**(15): 15682–704.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Pajares M, I Rojo A, Manda G, et al.: **Inflammation in parkinson's disease: mechanisms and therapeutic implications.** *Cells.* 2020; **9**(7): 1687.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Cheong JLY, de Pablo-Fernandez E, Foltynie T, et al.: **The association between type 2 diabetes mellitus and parkinson's disease.** *J Parkinsons Dis.* 2020; **10**(3): 775–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Pérez-Taboada I, Alberquilla S, Martín ED, et al.: **Diabetes causes dysfunctional dopamine neurotransmission favoring nigrostriatal degeneration in mice.** *Mov Disord.* 2020; **35**(9): 1636–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Lima MM, Targa AD, Nosedá AC, et al.: **Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?** *CNS Neurol Disord Drug Targets.* 2014; **13**(3): 418–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Oishi Y, Lazarus M: **The control of sleep and wakefulness by mesolimbic dopamine systems.** *Neurosci Res.* 2017; **118**: 66–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Korshunov KS, Blakemore LJ, Trombley PQ: **Dopamine: A modulator of circadian rhythms in the central nervous system.** *Front Cell Neurosci.* 2017; **11**: 91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Kesner AJ, Lovinger DM: **Wake up and smell the dopamine: new mechanisms mediating dopamine activity fluctuations related to sleep and psychostimulant sensitivity.** *Neuropsychopharmacology.* 2021; **46**(4): 683–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Alonso IP, Pino JA, Kortagere S, et al.: **Dopamine transporter function fluctuates across sleep/wake state: potential impact for addiction.** *Neuropsychopharmacology.* 2021; **46**(4): 699–708.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Winkelman JW, de Lecea L: **Sleep and neuropsychiatric illness.** *Neuropsychopharmacology.* 2020; **45**(1): 1–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Zhang F, Niu L, Liu X, et al.: **Rapid eye movement sleep behavior disorder and neurodegenerative diseases: an update.** *Aging Dis.* 2020; **11**(2): 315–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Ylikoski A, Martikainen K, Sarkanen T, et al.: **Parkinson's disease and narcolepsy-like symptoms.** *Sleep Med.* 2015; **16**(4): 540–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Haq IZ, Naidu Y, Reddy P, et al.: **Narcolepsy in Parkinson's disease.** *Expert Rev Neurother.* 2010; **10**(6): 879–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Fortuyn HA, Swinkels S, Buitelaar J, et al.: **High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study.** *Sleep.* 2008; **31**(3): 335–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Guilleminault C: **narcolepsy.** *Sleep Disorders Medicine.* Elsevier. 1994; 241–54.
[Publisher Full Text](#)
27. Miyagawa T, Tokunaga K: **Genetics of narcolepsy.** *Hum Genome Var.* 2019; **6**: 4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Wissemann WT, Hill-Burns EM, Zabetian CP, et al.: **Association of Parkinson disease with structural and regulatory variants in the HLA region.** *Am J Hum Genet.* 2013; **93**(5): 984–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Mignot E: **Genetic and familial aspects of narcolepsy.** *Neurology.* 1998; **50**(2 Suppl 1): S16–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Ebrahim IO, Howard RS, Kopelman MD, et al.: **The hypocretin/orexin system.** *J R Soc Med.* 2002; **95**(5): 227–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Bourgin P, Huitrón-Réndiz S, Spier AD, et al.: **Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons.** *J Neurosci.* 2000; **20**(20): 7760–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Thannickal TC, Lai YY, Siegel JM: **Hypocretin (orexin) cell loss in Parkinson's disease.** *Brain.* 2007; **130**(Pt 6): 1586–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. **Loss of hypocretin neurons might cause sleep disturbance in PD.** *Nat Rev Neurol.* 2007; **3**: 421–421.
[Publisher Full Text](#)
34. Calipari ES, España RA: **Hypocretin/orexin regulation of dopamine signaling: implications for reward and reinforcement mechanisms.** *Front Behav Neurosci.* 2012; **6**: 54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Delprato A: **Extended data workbook 1 LRRK2, HLA-DQB1, and HCRT gene correlates.xlsx.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.13072037.v1>
36. Delprato A: **Extended data workbook 5 PD, narcolepsy and IR risk factors genes.xlsx.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.13072151.v1>
37. Delprato A: **Extended data workbook 2 Cluster analysis of gene correlates.xlsx.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.13072103.v1>
38. Delprato A: **Extended data workbook 3 Common genes and functions.xlsx.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.13072124.v1>
39. Delprato A: **Extended data workbook 4 Keyword genes.xlsx.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.13072130.v1>
40. Xue A, Wu Y, Zhu Z, et al.: **Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.** *Nat Commun.* 2018; **9**(1): 2941.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Jin X, Li J, Li W, et al.: **Weighted gene co-expression network analysis reveals specific modules and biomarkers in Parkinson's disease.** *Neurosci Lett.* 2020; **728**: 134950.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Delprato A: **Extended data workbook 6 LRRK2, HLA-DQB1 and CAMK1D protein-protein interaction network.xlsx.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.13072160.v1>
43. Delprato A: **Extended data workbook 7 Gene expression patterns for AGER, BHLHE41, CACNA1C, CAMK1D, HMGB1 in the dorsal thalamus and subcoeruleus nucleus.xlsx.** [cited 2021 Sep 25].
<http://www.doi.org/10.6084/m9.figshare.16680571>
44. Hurlley MJ, Brandon B, Gentleman SM, et al.: **Parkinson's disease is associated with altered expression of Cav1 channels and calcium-binding proteins.** *Brain.* 2013; **136**(Pt 7): 2077–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Wang L, Maldonado L, Beecham GW, et al.: **DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient.** *Neurol Genet.* 2016; **2**(3): e72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Wang X, Saegusa H, Huntula S, et al.: **Blockade of microglial Cav1.2 Ca²⁺ channel exacerbates the symptoms in a Parkinson's disease model.** *Sci Rep.* 2019; **9**(1): 9138.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

47. Beilina A, Rudenko IN, Kaganovich A, *et al.*: **Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.** *Proc Natl Acad Sci U S A.* 2014; **111**(7): 2626–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Angelopoulou E, Piperi C, Papavassiliou AG: **High-mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches.** *J Neurochem.* 2018; **146**(3): 211–8. [PubMed Abstract](#) | [Publisher Full Text](#)
49. Yang W, Chang Z, Que R, *et al.*: **Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson's Disease Severity.** *Front Aging Neurosci.* 2020; **12**: 53. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Gao HM, Zhou H, Zhang F, *et al.*: **HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration.** *J Neurosci.* 2011; **31**(3): 1081–92. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Jiang X, Wang X, Tuo M, *et al.*: **RAGE and its emerging role in the pathogenesis of Parkinson's disease.** *Neurosci Lett.* 2018; **672**: 65–9. [PubMed Abstract](#) | [Publisher Full Text](#)
52. Wang X, Sun X, Niu M, *et al.*: **RAGE Silencing Ameliorates Neuroinflammation by Inhibition of p38-NF- κ B Signaling Pathway in Mouse Model of Parkinson's Disease.** *Front Neurosci.* 2020; **14**: 353. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Cho HJ, Xie C, Cai H: **AGE-induced neuronal cell death is enhanced in G2019S LRRK2 mutation with increased RAGE expression.** *Transl Neurodegener.* 2018; **7**: 1. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Gao J, Teng J, Liu H, *et al.*: **Association of RAGE gene polymorphisms with sporadic Parkinson's disease in Chinese Han population.** *Neurosci Lett.* 2014; **559**: 158–62. [PubMed Abstract](#) | [Publisher Full Text](#)
55. Menting JG, Whittaker J, Margetts MB, *et al.*: **How insulin engages its primary binding site on the insulin receptor.** *Nature.* 2013; **493**(7431): 241–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Pausch MH, Kaim D, Kunisawa R, *et al.*: **Multiple Ca²⁺/calmodulin-dependent protein kinase genes in a unicellular eukaryote.** *EMBO J.* 1991; **10**(6): 1511–22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Lee KH, Wucherpfennig KW, Wiley DC: **Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes.** *Nat Immunol.* 2001; **2**(6): 501–7. [PubMed Abstract](#) | [Publisher Full Text](#)
58. Kim HS, Jung MS, Lee K, *et al.*: **An S-locus receptor-like kinase in plasma membrane interacts with calmodulin in *Arabidopsis*.** *FEBS Lett.* 2009; **583**(1): 36–42. [PubMed Abstract](#) | [Publisher Full Text](#)
59. Meixner A, Boldt K, Van Troys M, *et al.*: **A QUICK screen for Lrrk2 interaction partners—leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.** *Mol Cell Proteomics.* 2011; **10**(1): M110.001172. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Mamelak M: **Parkinson's disease, the dopaminergic neuron and gamma-hydroxybutyrate.** *Neurol Ther.* 2018; **7**(1): 5–11. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Sergi D, Renaud J, Simola N, *et al.*: **Diabetes, a contemporary risk for Parkinson's disease: epidemiological and cellular evidences.** *Front Aging Neurosci.* 2019; **11**: 302. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Fiory F, Perruolo G, Cimmino I, *et al.*: **The relevance of insulin action in the dopaminergic system.** *Front Neurosci.* 2019; **13**: 868. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Mahoney CE, Cogswell A, Korolnik IJ, *et al.*: **The neurobiological basis of narcolepsy.** *Nat Rev Neurosci.* 2019; **20**(2): 83–93. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Schuld A, Hebebrand J, Geller F, *et al.*: **Increased body-mass index in patients with narcolepsy.** *Lancet.* 2000; **355**(9211): 1274–5. [PubMed Abstract](#) | [Publisher Full Text](#)
65. Hogg E, Athreya K, Basile C, *et al.*: **High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson's Disease.** *J Parkinsons Dis.* 2018; **8**(2): 259–65. [PubMed Abstract](#) | [Publisher Full Text](#)
66. Pellegriano R, Kavakli IH, Goel N, *et al.*: **A novel *BHLHE41* variant is associated with short sleep and resistance to sleep deprivation in humans.** *Sleep.* 2014; **37**(8): 1327–36. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. **Intranasal Insulin May Ease Parkinson's Cognitive and Motor Symptoms, Early Study Shows n.d.** (accessed September 7, 2020). [Reference Source](#)
68. Li Y, Li L, Hölscher C: **Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases.** *Rev Neurosci.* 2016; **27**(7): 689–711. [PubMed Abstract](#) | [Publisher Full Text](#)
69. Ai H, Fang W, Hu H, *et al.*: **Antidiabetic Drug Metformin Ameliorates Depressive-Like Behavior in Mice with Chronic Restraint Stress via Activation of AMP-Activated Protein Kinase.** *Aging Dis.* 2020; **11**(1): 31–43. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Chu JS, Liu TH, Wang KL, *et al.*: **The Metabolic Activity of Caudate and Prefrontal Cortex Negatively Correlates with the Severity of Idiopathic Parkinson's Disease.** *Aging Dis.* 2019; **10**(4): 847–53. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Zhu S, Deng B, Huang Z, *et al.*: **"Hot cross bun" is a potential imaging marker for the severity of cerebellar ataxia in MSA-C.** *NPJ Parkinsons Dis.* 2021; **7**(1): 15. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. Pandi-Perumal SR, BaHammam AS, Brown GM, *et al.*: **Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.** *Neurotox Res.* 2013; **23**(3): 267–300. [PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status: ? ✓ ✓

Version 2

Reviewer Report 02 November 2021

<https://doi.org/10.5256/f1000research.78075.r97492>

© 2021 Enterría-Morales D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Daniel Enterría-Morales

Neurobiology Section, Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA

After reviewing the revised version of the manuscript, there are only three minor points that I would like to highlight:

1. This paragraph seems to be duplicated in the "Discussion" section: "Silencing of the RAGE pathway in a mouse model of PD improved neuroinflammation which causes dopaminergic neurodegeneration in PD patients⁵². This is important because the deterioration of dopaminergic neurons in the brain is believed to play a critical role in the development of PD⁶⁰. By the time clinical signs of PD are identified and a diagnosis is made, a large number of dopaminergic neurons have already been lost¹. Dopaminergic neurons are also involved in promoting feeding behavior in the hypoglycemic state which is mediated by insulin receptors in the substantia nigra, indicating that dopaminergic neuronal loss may alter glycemic control^{61,62}. Loss of orexin/hypocretin is also linked to binge-eating behavior, low BMR, and obesity, which is a symptom of narcolepsy⁶³⁻⁶⁵".
2. The link to open the Extended data Table 1 has a typographical error. It is listed as <https://doi.org/10.6084/m9.figshare.16692085>, but the right link is <https://doi.org/10.6084/m9.figshare.16692085>.
3. In the 'Results' section, the authors mention that "CACNA1C expression was also confirmed at the protein level by immunocytochemistry in the mouse hypothalamus and pons/medulla. Data are provided in *Extended data*, Table 1". However, in this table there is no data or images showing the immunocytochemistry of CACNA1C in the mouse tissue mentioned above. Also, if this technique has been carried out with mouse tissue, it should be considered as immunohistochemistry. I suggest that the authors add the data to this table, or remove this sentence from this paragraph.

All my comments and questions have been addressed, so the manuscript will be ready for publication after these minor errors have been corrected.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neurodegeneration, Parkinson's disease, Neurochemistry.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 02 Jan 2022

Anna Delprato, BioScience Project, Wakefield, USA

Thank you for reviewing version 2 of our article and catching these edits. We have incorporated the indicated corrections in a new version.

Competing Interests: No competing interests to declare

Reviewer Report 21 October 2021

<https://doi.org/10.5256/f1000research.78075.r97494>

© 2021 Wang Q. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Qing Wang

Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

The authors have fully addressed my concerns, and it would be accepted.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: The authors have fully addressed my concerns, and it would be accepted.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 06 May 2021

<https://doi.org/10.5256/f1000research.30294.r83029>

© 2021 Enterría-Morales D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Daniel Enterría-Morales

Neurobiology Section, Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA

Parkinson's disease is the second most common neurodegenerative disease right after Alzheimer's disease nowadays. There is no treatment to counteract the symptoms of the disease, and most of the medications used are aimed at alleviating the symptoms. However, the use of these drugs also has disadvantages in the form of side effects, which makes the quality of life of the patients drop drastically. Lately, research on Parkinson's disease has been focused on the detection of markers that allow diagnosis of this disorder in early stages to increase the probabilities of treatments being effective. Within these types of studies, we have this article published by Chunduri *et al.*, in which the main objective is the search for the expression of certain genes shared between Parkinson's disease, insulin resistance and narcolepsy. The authors propose to analyze the molecular bases of the comorbidity of these three disorders in order to find risk factors that could predispose and facilitate the early diagnosis of Parkinson's disease. As a result of the study, the authors have identified several genes that are related to the signaling pathways of dopamine, insulin and the immune system, among which are: CACNA1C, CAMK1D, BHLHE41, HMGB1, and the AGE-RAGE axis.

The preliminary data obtained in this study is interesting and would allow further research on the early diagnosis of this disorder, through the individualized study of each of these candidate genes, probably through knock-out or knock-down strategies in animal models. However, some parts of the article need to be supplemented with additional data, and furthermore, the discussion of the data obtained seems short and incomplete, so the authors should increase the number of bibliographic references that are currently discussing the analysis of comorbidity in Parkinson's disease, both in animal models and in humans.

Specifically, I would like the authors to address the following points:

1. It would be appropriate to validate the expression of some of these candidate genes in the mentioned brain regions, in the tissue of healthy human or wild-type animals (e.g. mouse, rat, monkey), mainly by quantitative PCR or in situ hybridization, or alternatively by Western Blot or immunohistochemistry. It would be very interesting if the authors could also analyze the expression of these genes in tissue from patients or animal models of Parkinson's disease.
2. It would be quite useful to validate the data obtained in humans, with the gene expression database available for mouse or monkey brain tissue, on the Allen Brain Institute website. Mouse Brain Atlas: <https://developingmouse.brain-map.org/search/index>
Non-human primate Brain Atlas: <https://www.blueprintnhpatlas.org/microarray/search>
3. It would be great if the authors could comment on why they decided to analyze specifically the comorbidity of Parkinson's disease with insulin resistance and narcolepsy. There are other disorders that are more frequent comorbidities in Parkinson's disease patients, such

as hypertension, Crohn's disease, schizophrenia, restless leg syndrome, anemia (see attached references).^{1,2,3}

4. Could the authors comment and discuss if some of the candidate genes found are expressed in dopaminergic neurons in the human or mouse brain (regarding the bibliography available in the field)?
5. I suggest that the authors should cite more relevant references in the discussion section (see list of references attached).^{4,5,6,7,8,9,10,11,12,13,14,15,16,17}

Once the authors are able to address all the issues I have proposed in this report, I would be willing to re-evaluate this manuscript.

References

1. Nalls MA, Saad M, Noyce AJ, Keller MF, et al.: Genetic comorbidities in Parkinson's disease. *Hum Mol Genet.* 2014; **23** (3): 831-41 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Santos García D, Suárez Castro E, Expósito I, de Deus T, et al.: Comorbid conditions associated with Parkinson's disease: A longitudinal and comparative study with Alzheimer disease and control subjects. *J Neurol Sci.* 2017; **373**: 210-215 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Santiago JA, Bottero V, Potashkin JA: Biological and Clinical Implications of Comorbidities in Parkinson's Disease. *Front Aging Neurosci.* 2017; **9**: 394 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Wang L, Maldonado L, Beecham GW, Martin ER, et al.: DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. *Neurol Genet.* 2016; **2** (3): e72 [PubMed Abstract](#) | [Publisher Full Text](#)
5. Wang X, Saegusa H, Huntula S, Tanabe T: Blockade of microglial Cav1.2 Ca²⁺ channel exacerbates the symptoms in a Parkinson's disease model. *Scientific Reports.* 2019; **9** (1). [Publisher Full Text](#)
6. Hurley MJ, Brandon B, Gentleman SM, Dexter DT: Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. *Brain.* 2013; **136** (Pt 7): 2077-97 [PubMed Abstract](#) | [Publisher Full Text](#)
7. Angelopoulou E, Piperi C, Papavassiliou AG: High-mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches. *J Neurochem.* **146** (3): 211-218 [PubMed Abstract](#) | [Publisher Full Text](#)
8. Sasaki T, Liu K, Agari T, Yasuhara T, et al.: Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease. *Exp Neurol.* 2016; **275 Pt 1**: 220-31 [PubMed Abstract](#) | [Publisher Full Text](#)
9. Huang J, Yang J, Shen Y, Jiang H, et al.: HMGB1 Mediates Autophagy Dysfunction via Perturbing Beclin1-Vps34 Complex in Dopaminergic Cell Model. *Front Mol Neurosci.* 2017; **10**: 13 [PubMed Abstract](#) | [Publisher Full Text](#)
10. Santoro M, Maetzler W, Stathakos P, Martin HL, et al.: In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. *Neurobiol Dis.* **91**: 59-68 [PubMed Abstract](#) | [Publisher Full Text](#)
11. Gao HM, Zhou H, Zhang F, Wilson BC, et al.: HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. *J Neurosci.* 2011; **31** (3): 1081-92 [PubMed Abstract](#) | [Publisher Full Text](#)
12. Derk J, MacLean M, Juranek J, Schmidt AM: The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration. *J Alzheimers Dis Parkinsonism.* 2018; **8**

(1). [PubMed Abstract](#) | [Publisher Full Text](#)

13. Jiang X, Wang X, Tuo M, Ma J, et al.: RAGE and its emerging role in the pathogenesis of Parkinson's disease. *Neuroscience Letters*. 2018; **672**: 65-69 [PubMed Abstract](#) | [Publisher Full Text](#)

14. Teismann P, Sathe K, Bierhaus A, Leng L, et al.: Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. *Neurobiol Aging*. 2012; **33** (10): 2478-90 [PubMed Abstract](#) | [Publisher Full Text](#)

15. Cho HJ, Xie C, Cai H: AGE-induced neuronal cell death is enhanced in G2019S LRRK2 mutation with increased RAGE expression. *Transl Neurodegener*. 2018; **7**: 1 [PubMed Abstract](#) | [Publisher Full Text](#)

16. Salahuddin P, Rabbani G, Khan RH: The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach. *Cell Mol Biol Lett*. 2014; **19** (3): 407-37 [PubMed Abstract](#) | [Publisher Full Text](#)

17. Rungratanawanich W, Qu Y, Wang X, Essa MM, et al.: Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. *Exp Mol Med*. 2021; **53** (2): 168-188 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neurodegeneration, Parkinson's disease, Neurochemistry.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 29 Sep 2021

Anna Delprato, BioScience Project, Wakefield, USA

Reviewer 3

Parkinson's disease is the second most common neurodegenerative disease right after Alzheimer's disease nowadays. There is no treatment to counteract the symptoms of the disease, and most of the medications used are aimed at alleviating the symptoms. However, the use of these drugs also has disadvantages in the form of side effects, which makes the quality of life of the patients drop drastically. Lately, research on Parkinson's disease has been focused on the detection of markers that allow diagnosis of this disorder in early stages to increase the probabilities of treatments being effective. Within these types of studies, we have this article published by Chunduri et al., in which the main objective is the search for the expression of certain genes shared between Parkinson's disease, insulin resistance and narcolepsy. The authors propose to analyze the molecular bases of the comorbidity of these three disorders in order to find risk factors that could predispose and facilitate the early diagnosis of Parkinson's disease. As a result of the study, the authors have identified several genes that are related to the signaling pathways of dopamine, insulin and the immune system, among which are: CACNA1C, CAMK1D, BHLHE41, HMGB1, and the AGE-RAGE axis.

The preliminary data obtained in this study is interesting and would allow further research on the early diagnosis of this disorder, through the individualized study of each of these candidate genes, probably through knock-out or knock-down strategies in animal models. However, some parts of the article need to be supplemented with additional data, and furthermore, the discussion of the data obtained seems short and incomplete, so the authors should increase the number of bibliographic references that are currently discussing the analysis of comorbidity in Parkinson's disease, both in animal models and in humans.

Reviewer 3 comment:

Specifically, I would like the authors to address the following points:

It would be appropriate to validate the expression of some of these candidate genes in the mentioned brain regions, in the tissue of healthy human or wild-type animals (e.g. mouse, rat, monkey), mainly by quantitative PCR or in situ hybridization, or alternatively by Western Blot or immunohistochemistry. It would be very interesting if the authors could also analyze the expression of these genes in tissue from patients or animal models of Parkinson's disease.

Response:

We have addressed the request for validation of candidate gene expression in the mentioned brain regions above in our response to Reviewer 1 and have added the information to the Results and Discussion sections of the revised manuscript. To summarize our findings, each of the key genes is expressed in at least two of the brain regions relevant to this study.

To address the reviewer's question concerning expression of these genes in tissue from patients or animal models of Parkinson's disease, we have analyzed the gene expression data available in the NCBI GEO database specifically for Parkinson's

Disease datasets to determine if any of the key genes identified in our study are differentially expressed.

Out of 24 available datasets, we found that BHLHE41 and AGER were differentially expressed as compared with controls from two distinct studies (<https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=GSE36321> and <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19587>).

For BHLHE41, the study involved assessing gene expression in human neural stem cells containing the LRRK2 (G2019S) pathogenic mutation. The LRRK2 (G2019S) containing cells had higher expression of BHLHE4. AGER was differentially expressed with borderline significance in a study that examined post mortem medullary regions from brains with evidence of Parkinson's. AGER was expressed higher in brains from individuals with Parkinson's. However, due to low n values we do not have enough confidence in the data to include these results in the manuscript. The other genes of interest, CACNA1C, CAMK1D, and HMGB1 were not identified in any of the GEO gene expression datasets as being expressed differently than controls.

We also assessed expression of the key genes in individuals with Parkinson's versus a healthy control group from data generated in a longitudinal study in which the aim is to identify biomarkers of Parkinson's disease progression (Parkinson's Progression Markers Initiative <https://www.ppmi-info.org/>). The Parkinson's cohort consisted of 423 individuals and the control group, 196. There was no difference in the expression for any of the key genes.

Reviewer 3 comment:

It would be quite useful to validate the data obtained in humans, with the gene expression database available for mouse or monkey brain tissue, on the Allen Brain Institute website. Mouse Brain Atlas: <https://developingmouse.brain-map.org/search/index>
Non-human primate Brain Atlas: <https://www.blueprintnpatlas.org/microarray/search>

Response:

Thank you for the suggestion. However, to the best of our knowledge, there is no Microarray data available for mouse at the Allen Brain Atlas but we were able to consider the in situ hybridization data (discussed above). Regrettably the Non-human primate atlas does not contain data for the relevant brain regions used in this study which is unfortunate because this is an intriguing dataset.

Reviewer 3 comment:

It would be great if the authors could comment on why they decided to analyze specifically the comorbidity of Parkinson's disease with insulin resistance and narcolepsy. There are other disorders that are more frequent comorbidities in Parkinson's disease patients, such as hypertension, Crohn's disease, schizophrenia, restless leg syndrome, anemia (see attached references).^{1,2,3}

Response:

Initially, the focus of our study was to investigate the connection between Parkinson's and narcolepsy. Early on in the data collection and preliminary analysis, we observed that many of the gene correlates were linked to insulin resistance. On the basis of this finding we decided to expand the scope of the study.

Reviewer 3 comment:

Could the authors comment and discuss if some of the candidate genes found are expressed in dopaminergic neurons in the human or mouse brain (regarding the bibliography available in the field)?

Response:

AGER, BHLHE41, CACNA1C, and HMGB1 are expressed in Dopaminergic neurons from the substantia nigra pars compacta and ventral tegmental area in rats. These data are publicly accessible at GEO datasets, accession number: GSE1837 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1837>).

There is also further support from previously published studies: CACNA1C (PTSD study generated mice with specific deletion of cacna1c from D1R-expressing neurons <https://pubmed.ncbi.nlm.nih.gov/32332995/>).

CAMK1D (Decreased mRNA Expression of Key ER Ca²⁺ Regulators and CamK1D in LRRK2 G2019S NeuronsD <https://www.sciencedirect.com/science/article/pii/S2213671118304909>)

HMGB1/RAGE/AGER (Activation of the HMGB1-RAGE axis upregulates TH expression in dopaminergic neurons via JNK phosphorylation <https://pubmed.ncbi.nlm.nih.gov/28887039>)

Reviewer 3 comment:

I suggest that the authors should cite more relevant references in the discussion section (see list of references attached).4,5,6,7,8,9,10,11,12,13,14,15,16,17

Response:

We thank the reviewer for providing these references. We have updated the Introduction and Discussion sections of the revised manuscript to include this information.

Competing Interests: No competing interests were disclosed.

Reviewer Report 12 April 2021

<https://doi.org/10.5256/f1000research.30294.r82398>

© 2021 Wang Q. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Qing Wang

Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

This study has identified the genes such as *CACNA1C*, *CAMK1D*, *BHLHE41*, *HMGB1*, and AGE-RAGE that link PD with narcolepsy and insulin resistance and their signaling networks are connected through insulin and immune system pathways. These findings may contribute to develop new treatment strategies in PD patients as well as individuals with diabetes and narcolepsy. The results of the study are interesting.

However, the introduction and discussion are too weak. So it is suggested to cite more relevant references as follows (please see the reference list below) in order to elaborate on the mechanisms.

After my concerns above have been fully addressed, I am happy to re-evaluate this manuscript.

References

1. Ai H, Fang W, Hu H, Hu X, et al.: Antidiabetic Drug Metformin Ameliorates Depressive-Like Behavior in Mice with Chronic Restraint Stress via Activation of AMP-Activated Protein Kinase. *Aging Dis.* 2020; **11** (1): 31-43 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Wang T, Yuan F, Chen Z, Zhu S, et al.: Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinson's disease patients with type 2 diabetes mellitus. *Aging.* 2020; **12** (15): 15682-15704 [Publisher Full Text](#)
3. Chu JS, Liu TH, Wang KL, Han CL, et al.: The Metabolic Activity of Caudate and Prefrontal Cortex Negatively Correlates with the Severity of Idiopathic Parkinson's Disease. *Aging Dis.* 2019; **10** (4): 847-853 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Guo Y, Zhang C, Shang FF, Luo M, et al.: Ketogenic Diet Ameliorates Cardiac Dysfunction via Balancing Mitochondrial Dynamics and Inhibiting Apoptosis in Type 2 Diabetic Mice. *Aging Dis.* 2020; **11** (2): 229-240 [PubMed Abstract](#) | [Publisher Full Text](#)
5. Zhu S, Deng B, Huang Z, Chang Z, et al.: "Hot cross bun" is a potential imaging marker for the severity of cerebellar ataxia in MSA-C. *NPJ Parkinsons Dis.* 2021; **7** (1): 15 [PubMed Abstract](#) | [Publisher Full Text](#)
6. Han R, Liu Z, Sun N, Liu S, et al.: BDNF Alleviates Neuroinflammation in the Hippocampus of Type 1 Diabetic Mice via Blocking the Aberrant HMGB1/RAGE/NF- κ B Pathway. *Aging Dis.* 2019; **10** (3): 611-625 [PubMed Abstract](#) | [Publisher Full Text](#)
7. Wang L, Liu Y, Yan S, Du T, et al.: Disease Progression-Dependent Expression of CD200R1 and CX3CR1 in Mouse Models of Parkinson's Disease. *Aging Dis.* 2020; **11** (2): 254-268 [PubMed Abstract](#) | [Publisher Full Text](#)
8. Zhu S, Li H, Deng B, Zheng J, et al.: Various Diseases and Clinical Heterogeneity Are Associated

- With "Hot Cross Bun". *Front Aging Neurosci.* 2020; **12**: 592212 [PubMed Abstract](#) | [Publisher Full Text](#)
9. Gao X, Huang Z, Feng C, Guan C, et al.: Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson's disease. *Briefings in Bioinformatics.* 2020. [Publisher Full Text](#)
10. Han F, Li X, Yang J, Liu H, et al.: Salsalate Prevents β -Cell Dedifferentiation in OLETF Rats with Type 2 Diabetes through Notch1 Pathway. *Aging Dis.* 2019; **10** (4): 719-730 [PubMed Abstract](#) | [Publisher Full Text](#)
11. Zou J, Chen Z, Wei X, Chen Z, et al.: Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units. *Cell Death & Disease.* 2017; **8** (6). [Publisher Full Text](#)
12. Gao L, Yu S, Cipriani A, Wu S, et al.: Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. *Aging Dis.* 2019; **10** (6): 1311-1319 [PubMed Abstract](#) | [Publisher Full Text](#)
13. Zhang F, Niu L, Liu X, Liu Y, et al.: Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update. *Aging Dis.* 2020; **11** (2): 315-326 [PubMed Abstract](#) | [Publisher Full Text](#)
14. Ma WX, Tang J, Lei ZW, Li CY, et al.: Potential Biochemical Mechanisms of Brain Injury in Diabetes Mellitus. *Aging Dis.* 2020; **11** (4): 978-987 [PubMed Abstract](#) | [Publisher Full Text](#)
15. Yuan F, Guo X, Wei X, Xie F, et al.: Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis. *Eur J Neurol.* **27** (10): 1957-1970 [PubMed Abstract](#) | [Publisher Full Text](#)
16. Yang W, Chang Z, Que R, Weng G, et al.: Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson's Disease Severity. *Front Aging Neurosci.* 2020; **12**: 53 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of

expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 29 Sep 2021

Anna Delprato, BioScience Project, Wakefield, USA

Reviewer 2

This study has identified the genes such as CACNA1C, CAMK1D, BHLHE41, HMGB1, and AGE-RAGE that link PD with narcolepsy and insulin resistance and their signaling networks are connected through insulin and immune system pathways. These findings may contribute to developing new treatment strategies in PD patients as well as individuals with diabetes and narcolepsy. The results of the study are interesting.

Reviewer 2 comment:

However, the introduction and discussion are too weak. So it is suggested to cite more relevant references as follows (please see the reference list below) in order to elaborate on the mechanisms. After my concerns above have been fully addressed, I am happy to re-evaluate this manuscript.

Response:

We thank the reviewer for providing us with many relevant references. Based on this information we have revised the Introduction and Discussion sections of the manuscript and have included more mechanistic detail and context as recommended.

Competing Interests: No competing interests were disclosed.

Reviewer Report 08 February 2021

<https://doi.org/10.5256/f1000research.30294.r77250>

© 2021 Hashimoto M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Makoto Hashimoto

Laboratory for Parkinson's disease, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

Comorbidity of Parkinson's disease (PD) with insulin resistance (IR) and narcolepsy-like sleep patterns are frequently described, but the mechanism is unclear.

In this study, an integrative genomics and systems biology approach was used to analyze gene expression patterns associated with PD, IR, and narcolepsy to identify genes and pathways that may shed light on how these disorders are interrelated. The results showed that the PD and narcolepsy signaling networks are connected through insulin and immune system pathways. Important genes and pathways that link PD, narcolepsy, and IR were shown to be *CACNA1C*,

CAMK1D, *BHLHE41*, *HMGB1*, and AGE-RAGE. The authors concluded that these findings might aid in the design of early intervention strategies and treatment regimes for non-motor symptoms in PD patients as well as individuals with diabetes and narcolepsy.

Overall, the results are interesting and clear. I agree that the paper may contribute to the PD research. My comments are as follows:

1. It would be much better if modification of the expression of the identified genes (knockout or overexpression), including *CACNA1C*, *CAMK1D*, *BHLHE41*, *HMGB1*, and AGE-RAGE, might result in phenotypes related to PD and/or narcolepsy in cells or animal models. Are there such previous papers? Otherwise, the result of network analysis alone seems preliminary.
2. In the same context, other experiments, such as immunohistochemistry, should be conducted to confirm the expression of these genes at the protein level.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: neurodegenerative diseases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Mar 2021

Anna Delprato, BioScience Project, Wakefield, USA

We would like to thank you for taking the time to review our article and providing constructive feedback. We will submit a revised version once we have received all of the reviews.

Competing Interests: No competing interests were disclosed.

Author Response 29 Sep 2021

Anna Delprato, BioScience Project, Wakefield, USA

Reviewer 1

Comorbidity of Parkinson's disease (PD) with insulin resistance (IR) and narcolepsy-like sleep patterns are frequently described, but the mechanism is unclear.

In this study, an integrative genomics and systems biology approach was used to analyze gene expression patterns associated with PD, IR, and narcolepsy to identify genes and pathways that may shed light on how these disorders are interrelated. The results showed that the PD and narcolepsy signaling networks are connected through insulin and immune system pathways. Important genes and pathways that link PD, narcolepsy, and IR were shown to be CACNA1C, CAMK1D, BHLHE41, HMGB1, and AGE-RAGE. The authors concluded that these findings might aid in the design of early intervention strategies and treatment regimes for non-motor symptoms in PD patients as well as individuals with diabetes and narcolepsy.

Overall, the results are interesting and clear. I agree that the paper may contribute to the PD research. My comments are as follows:

Reviewer 1 comment:

It would be much better if modification of the expression of the identified genes (knockout or overexpression), including CACNA1C, CAMK1D, BHLHE41, HMGB1, and AGE-RAGE, might result in phenotypes related to PD and/or narcolepsy in cells or animal models.

Are there such previous papers? Otherwise, the result of network analysis alone seems Preliminary.

Response:

We thank the reviewer for taking the time to provide us constructive feedback on this manuscript. There is in fact a great deal of evidence derived from knockout and cell based studies linking CACNA1C, HMGB1, and AGER/AGE-RAGE to Parkinson's pathogenesis. CACNA1C is also associated with Circadian rhythm and narcolepsy. In addition, CAMK1D is a component of the calmodulin dependent calcium signaling cascade and there is also support for its role as an interactor of LRRK2, one of the key genes influencing Parkinson's. HMGB1 and AGER/AGE-RAGE appear to act in concert mediating inflammatory processes that ultimately lead to neuron cell death via NF-κB signaling. AGER/AGE-RAGE and LRRK2 are also linked as RAGE proteins are upregulated in LRRK2 G2019S mutant cells. The LRRK2 G2019S mutation is the most common genetic cause of neurodegeneration and PD. The other major gene of interest identified in the ppi network, BHLHE41, is a transcription factor associated with Circadian processes. Variants of BHLHE41 have been implicated in short sleep syndrome and this gene also has a role in immune function. BHLHE41 in addition to CAMK1D, RAGE, and HMGB1 are also implicated in diabetes.

Details of the supporting studies for the candidate genes as well as the other network

genes have been included in the Introduction and Discussion sections of the revised manuscript.

Reviewer 1 comment:

In the same context, other experiments, such as immunohistochemistry, should be conducted to confirm the expression of these genes at the protein level.

Response:

We agree that the above mentioned studies could be useful to further support the results presented here. Regrettably we do not have access to wet lab facilities. Our method of research is based in bioinformatics, systems biology and integrative genomics.

However, we were able to address your question using legacy datasets from the Human Protein Atlas (<https://www.proteinatlas.org/>) which also contains data for gene expression in mice and pigs and the human database in the Allen Brain Atlas (<https://human.brain-map.org/microarray/search>).

Results for gene expression of the key genes in the hypothalamus and pons are as follows: Each of the genes with the exception of AGER were expressed in both the hypothalamus and pons for human, mouse and pig. CACNA1C expression was also confirmed at the protein level by immunocytochemistry in the mouse hypothalamus and pons/medulla.

The expression pattern of the key genes in dorsal thalamus and subcoeruleus nucleus data were obtained for humans only and are as follows: HMGB1, AGER, BHLHE41 are expressed in both the dorsal thalamus and subcoeruleus nucleus. CACNA1C is expressed in the dorsal thalamus and is not expressed in the subcoeruleus nucleus. CAMK1D was not expressed in either the dorsal thalamus or subcoeruleus nucleus. These data have been added to the revised version of the manuscript.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research